Becton, Dickinson and Company

Becton, Dickinson and Company

BDXยทNYSE

$145.61

+0.19%
HealthcareMedical - Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

At a Glance

Live Snapshot
Market Cap$52.75B
EPS5.8400
P/E Ratio24.93
Earnings Date08/06/2026
Becton, Dickinson and Company

Becton, Dickinson and Company Fair Value Envelope

BDX ยท NYSE

Our analysis suggests that BDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $145.61, this represents a potential HIDDEN relative to our calculated worth for Becton, Dickinson and Company.

Intrinsic Value
Current Price: $145.61

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value$18.3B
+ Cash & Equivalents$851.0M
Firm Value$19.2B
- Debt$19.2B
Equity Value-$8.7M
/ Shares Outstanding286,627,469B
DCF Value-$0
OVERVALUED BY 100%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
$3.0B
$2.6B
$2.3B
$2.0B
$1.7B
$1.5B
$1.3B
$1.1B
$970.7M
$843.7M
Maintenance CapEx
-$132.1M
-$114.8M
-$99.8M
-$86.7M
-$75.4M
-$65.5M
-$56.9M
-$49.5M
-$43.0M
-$37.4M
Owner Earnings
$2.8B
$2.5B
$2.2B
$1.9B
$1.6B
$1.4B
$1.2B
$1.1B
$927.7M
$806.3M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
$2.6B
$2.1B
$1.7B
$1.4B
$1.1B
$890.4M
$716.6M
$576.7M
$464.1M
$373.5M
Terminal Value represents 34.7% of Enterprise Value